New hope for slowing a rare, inherited lung scaring disease
NCT ID NCT07443436
Summary
This study is testing whether a combination of three existing drugs (prednisone, azithromycin, and hydroxychloroquine) can slow the progression of a rare, inherited form of lung scarring. It will enroll 30 adults who have this specific genetic condition. The main goal is to see if this treatment can better preserve lung function over one year compared to standard care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.